US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Diamyd Medical announced today that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd[® ]in individuals recently diagnosed with type 1 diabetes. Following the decision from the FDA, DIAGNODE-3 is approved to start in the US.“This is a significant milestone for Diamyd Medical and more importantly, for patients diagnosed with type 1 diabetes,” comments Ulf Hannelius, CEO of Diamyd Medical. “We are looking forward